Abaloparatide benefits a wide range of postmenopausal women with osteoporosis
Tuesday, September 20, 2016 - 04:12
in Health & Medicine
A recent analysis of results from a randomized controlled clinical trial indicates that abaloparatide-SC, a novel therapy for osteoporosis, provides consistent protection against bone fractures in postmenopausal women with osteoporosis regardless of their baseline bone density, age, and previous history of fracture.